SoftWave Tissue Regeneration Technologies (SoftWave TRT) announces an exclusive agreement to supply Cynosure LLC with its patented extracorporeal shock wave devices for distribution in the United States and Canada primarily to medical doctors and their practices. 

“This agreement substantially increases doctors’ and patients’ access to our FDA cleared technology to accelerate healing, improve blood supply, activate connective tissue and to reduce pain and inflammation by leveraging Cynosure’s impeccable reputation and extensive sales force and marketing team. This agreement should quadruple our installed base over the next three years and provide extraordinary outcomes and benefits. This partnership will also allow Softwave TRT to focus our efforts on other fields of use, including Alzheimer’s, reduced opioid consumption, and cardiology and wound care,” he says.

— John Warlick, CEO of SoftWave Tissue Regeneration Technologies

SoftWave’s patented, unique technology triggers the body’s own biological healing response. SoftWave TRT devices offer a non-invasive procedure and require no anesthesia or numbing agents.

The patented SoftWave TRT technology deploys an unfocused extracorporeal shockwave (uESWT) that promotes both a physical and biological response to accelerate healing and tissue regeneration. The patented parabolic reflector produces a wider and deeper therapeutic energy zone resulting in reduced pain and superior patient outcomes by increasing blood supply, modulating inflammation, and stimulating, activating and recruiting resident and mesenchymal cells as described in published peer-reviewed research.

[Source(s): Softwave TRT, GlobeNewswire]